REG - Venture Life Group - Notice of Results <Origin Href="QuoteRef">VLG.L</Origin>

Venture LifeAnnouncement

07/09/2016 07:07

RNS Number : 1206J
Venture Life Group PLC
07 September 2016
7 September 2016
Venture Life Group plc
("Venture Life" or the "Group")
Notice of Interim Results
Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, will announce its Interim Results for the six months ended 30 June 2016 on 21 September 2016. 
A briefing for analysts will take place at the offices of Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Wednesday 21 September 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or emailventurelife@walbrookpr.com.
For further information, please contact: 
Venture Life Group PLC
+44 (0) 1344 742870
Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer 



Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
+44 (0) 20 7886 2500
Freddy Crossley/Peter Steel/Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking) 



Walbrook PR
venturelife@walbrookpr.comor
+44(0)207933 8780
Paul McManus
+44 (0) 7980 541 994
Anna Dunphy
+44 (0) 7876 741 001
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. 
The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.
Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NOREQLFBQKFXBBV